-
Sunvozertinib Tablets Approved for Marketing by China NMPA
2023-08-23
Recently, the Category 1 innovative drug Sunvozertinib Tablets (Chinese trade name: 舒沃哲) of Dizal (Jiangsu) Pharmaceutical Co., Ltd is approved by China NMPA.
-
Tafolecimab Injection Approved for Marketing by China NMPA
2023-08-16
Recently, the Tafolecimab Injection (trade name: SINTBILO®) of Innovent Biologics (Suzhou) Co., Ltd. is approved by China NMPA.
-
TCM Compound Preparation Pipa Qingfei Granules Approved for Marketing by China NMPA
2023-07-27
Recently, another traditional Chinese medicine (TCM) compound preparation Pipa Qingfei granules regulated as one of the ancient classic formulae (which is a category 3.1 innovative TCM) is approved for marketing through technical evaluation.
-
Cryoablation Equipment and Balloon Cryoablation Catheter Approved for Marketing
2023-08-24
Recently, the innovative products Cryoablation Equipment and Balloon Cryoablation Catheter of Cryofocus Medtech (Shanghai) Co., Ltd. are approved by China NMPA.
-
Magnetic Resonance Imaging System Approved for Marketing
2023-08-16
Recently, the innovative product Magnetic Resonance Imaging System of Wuhan Verlmagin Medical Technology Co., Ltd is approved by China NMPA.
-
Knee Replacement Surgical Navigation Positioning System Approved for Marketing
2023-07-13
Recently, the innovative product Knee Replacement Surgical Navigation Positioning System of Beijing Tinavi Medical Technologies Co., Ltd. is approved by China NMPA.
